SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
BCRX
--
0.00%
--
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication
GlobeNewswire · 13h ago
Long-term (48-week) Data Show Treatment with Berotralstat Provides Robust and Durable Reductions in HAE Attacks and Improvements in Quality of Life Scores
BioCryst Pharmaceuticals, Inc. (BCRX) today announced new data from the APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily berotralstat experienced sustained decreases in their attack frequency and
GlobeNewswire · 14h ago
COVID-19: Gilead's Remdesivir Might Be As Good As It Gets
Seeking Alpha - Article · 1d ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4d ago
BioCryst Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire · 5d ago
65 Biggest Movers From Yesterday
Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) shares climbed 386.3% to close at $19.21 on Thursday after the company announced the development program for its AB201 treatment of coronavirus associated with coagulopathy.
Benzinga · 05/29 09:35
BioCryst to Present at Jefferies Virtual Healthcare Conference
GlobeNewswire · 05/28 21:15
48 Stocks Moving In Thursday's Mid-Day Session
Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) shares jumped 207.6% to $12.15 after the company announced the development program for its AB201 treatment of coronavirus associated with coagulopathy.
Benzinga · 05/28 16:28
TWTR, HPQ among premarket losers
Seeking Alpha - Article · 05/28 13:14
28 Stocks Moving in Thursday's Pre-Market Session
Gainers
Benzinga · 05/28 11:34
BioCryst Pharma Late Wed. Priced ~18.7M Share Offering At $4.50/Share
Benzinga · 05/28 10:29
BioCryst prices equity offering
Seeking Alpha - Article · 05/28 08:26
BioCryst launches equity offering; shares down 5%
BioCryst Pharmaceuticals (NASDAQ:BCRX) initiates a $100M public offering of common stock. Price, volume and terms have yet to be announced. Shares down 5% 
seekingalpha · 05/28 01:50
BioCryst Plans to Raise $100 Million
Motley Fool · 05/27 23:21
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire · 05/27 21:01
BioCryst Commences Public Offering Of $100M Of Common Stock And Pre-Funded Warrants
Benzinga · 05/27 20:21
BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress
RESEARCH TRIANGLE PARK, N.C., May 26, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present new data on berotralstat (BCX7353), an.
GlobeNewswire · 05/26 11:00
Edited Transcript of BCRX earnings conference call or presentation 6-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 05/26 05:36
Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder
On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ:APLS) announced that it expects to file a marketing application in H2 seeking app
seekingalpha · 05/21 16:20
Moving Average Crossover Alert: BioCryst Pharmaceuticals
Zacks · 05/18 14:30